Celastrol

Celastrol

SCHEMBL15813281

CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)O)CC[C@]3(C)CC[C@@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 1.00
CCR6 P51684 1/20 1.00
PAX8 Q06710 1/20 1.00
TLR9 Q9NR96 1/20 1.00
NR4A1 P22736 7/20 0.84
PTPN1 P18031 1/20 0.83
CASP1 P29466 1/20 0.83
ABHD6 Q9BV23 1/20 0.83
KDM4E B2RXH2 1/20 0.83
TP53 P04637 1/20 0.83
CYP3A4 P08684 1/20 0.83
MAPT P10636 1/20 0.83
HPGD P15428 1/20 0.83
ALOX15 P16050 1/20 0.83
ALOX12 P18054 1/20 0.83
MAPK1 P28482 1/20 0.83
SMN1; SMN2 Q16637 1/20 0.83
TDP1 Q9NUW8 1/20 0.83
TERT O14746 7/20 0.82
HSP90AB1 P08238 5/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Celastrol SCHEMBL17130559 1.00 HSP90AA1 (1.00) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL14954 1.00 HSP90AA1 (1.00) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL25510440 1.00 HSP90AA1 (1.00) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL19745423 1.00 HSP90AA1 (1.00) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL17430781 1.00 HSP90AA1 (1.00) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL18845540 1.00 HSP90AA1 (1.00) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL20547678 0.99 HSP90AA1 (0.98) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL12395103 0.93 HSP90AA1 (0.86) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL13287257 0.92 HSP90AA1 (0.86) HSP90AA1CCR6PAX8TLR9NR4A1
Celastrol SCHEMBL23777521 0.92 HSP90AA1 (0.84) HSP90AA1CCR6PAX8TLR9NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024108024-A1 CELASTROL SALTS, CRYSTALLINE FORMS, AND USES THEREOF ERX PHARMACEUTICALS, INC. (US) 2024-05-23 WO claimed
WO-2024108024-A1 CELASTROL SALTS, CRYSTALLINE FORMS, AND USES THEREOF ERX PHARMACEUTICALS, INC. (US) 2024-05-23 WO disclosed
EP-4085919-A2 COMPOSITIONS AND METHODS TO TREAT CANCER Novartis AG (CH) 2022-11-09 EP disclosed
US-20210155932-A1 COMPOSITIONS AND METHODS TO TREAT CANCER NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2021-05-27 US disclosed
US-20210077453-A1 INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS UNIVERSITE DE STRASBOURG (FR) 2021-03-18 US disclosed
US-10765687-B2 Methods and compounds to inhibit enveloped virus release NORTHWESTERN UNIVERSITY (US) 2020-09-08 US disclosed
US-20190209589-A1 Methods and Compounds to Inhibit Enveloped Virus Release NORTHWESTERN UNIVERSITY (US) 2019-07-11 US disclosed
US-10300080-B2 Methods and compounds to inhibit enveloped virus release NORTHWESTERN UNIVERSITY (US) 2019-05-28 US disclosed
US-20190142782-A1 INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS INSERM-INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) 2019-05-16 US disclosed
US-20170095485-A1 METHODS AND COMPOUNDS TO INHIBIT ENVELOPED VIRUS RELEASE The Research Foundation for the State of University of New York 2017-04-06 US disclosed
US-20150064115-A1 NEUROPHILIC NANOPARTICLES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2015-03-05 US disclosed
US-20140179637-A1 METHODS AND COMPOUNDS TO INHIBIT ENVELOPED VIRUS RELEASE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170095485-A1 METHODS AND COMPOUNDS TO INHIBIT ENVELOPED VIRUS RELEASE SARS1, EEA1, ZC3HAV1 HSP90AA1 1573/4885CCR6 1764/4885PAX8 4612/4885
US-20140179637-A1 METHODS AND COMPOUNDS TO INHIBIT ENVELOPED VIRUS RELEASE SARS1, EEA1, ZC3HAV1 HSP90AA1 1573/4885CCR6 1764/4885PAX8 4612/4885
US-20210155932-A1 COMPOSITIONS AND METHODS TO TREAT CANCER TP53, BRCA1, NTPCR HSP90AA1 802/4885CCR6 3360/4885PAX8 3989/4885
US-10300080-B2 Methods and compounds to inhibit enveloped virus release SARS1, EEA1, ZC3HAV1 HSP90AA1 1573/4885CCR6 1764/4885PAX8 4612/4885
US-20190209589-A1 Methods and Compounds to Inhibit Enveloped Virus Release SARS1, EEA1, ZC3HAV1 HSP90AA1 1573/4885CCR6 1764/4885PAX8 4612/4885
US-10765687-B2 Methods and compounds to inhibit enveloped virus release SARS1, EEA1, ZC3HAV1 HSP90AA1 1573/4885CCR6 1764/4885PAX8 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.